Insider Transactions in Q4 2021 at Dicerna Pharmaceuticals Inc (DRNA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,973
-100.0%
|
$264,974
$38.25 P/Share
|
|
Dec 28
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,367
-100.0%
|
$89,946
$38.25 P/Share
|
|
Dec 28
2021
|
J Kevin Buchi Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,666
-100.0%
|
$177,308
$38.25 P/Share
|
|
Dec 28
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,813
-100.0%
|
$562,894
$38.25 P/Share
|
|
Dec 28
2021
|
Stephen K Doberstein Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Douglas Fambrough Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
231,431
-100.0%
|
$8,794,378
$38.25 P/Share
|
|
Dec 28
2021
|
Martin I Freed Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Patrick M. Gray Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
Stephen J Hoffman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,157
-100.0%
|
$613,966
$38.25 P/Share
|
|
Dec 28
2021
|
Marc D Kozin Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
$190,000
$38.25 P/Share
|
|
Dec 28
2021
|
Marc D Kozin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,333
-100.0%
|
$240,654
$38.25 P/Share
|
|
Dec 28
2021
|
Douglas W. Pagan Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,775
-100.0%
|
$295,450
$38.25 P/Share
|
|
Dec 28
2021
|
Cynthia Smith Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 28
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
18,100
-100.0%
|
$687,800
$38.25 P/Share
|
|
Dec 28
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,032
-100.0%
|
$191,216
$38.25 P/Share
|
|
Dec 28
2021
|
Adam Koppel Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,080,237
-100.0%
|
$117,049,006
$38.25 P/Share
|
|
Dec 28
2021
|
Adam Koppel Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,333
-100.0%
|
$126,654
$38.25 P/Share
|
|
Dec 15
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-13.0%
|
$28,576
$38.05 P/Share
|
|
Dec 15
2021
|
Ling Zeng Chief Legal Officer & Sec'y |
BUY
Exercise of conversion of derivative security
|
Direct |
2,562
+30.7%
|
-
|
|
Dec 15
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-41.44%
|
$63,650
$38.05 P/Share
|
|
Dec 15
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
3,775
+48.29%
|
-
|
|
Dec 15
2021
|
Douglas Fambrough Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,348
-2.26%
|
$203,224
$38.05 P/Share
|
|
Dec 15
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+5.49%
|
-
|
|
Dec 15
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,675
-8.47%
|
$63,650
$38.05 P/Share
|
|
Dec 15
2021
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
3,775
+16.03%
|
-
|
|
Dec 15
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
833
-10.67%
|
$31,654
$38.05 P/Share
|
|
Dec 15
2021
|
Shreeram Aradhye EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,837
+26.66%
|
-
|
|
Dec 15
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,241
-7.73%
|
$47,158
$38.05 P/Share
|
|
Dec 15
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,425
+17.58%
|
-
|
|
Dec 15
2021
|
Douglas W. Pagan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
602
-7.19%
|
$22,876
$38.05 P/Share
|
|
Dec 15
2021
|
Douglas W. Pagan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,050
+19.66%
|
-
|
|
Dec 13
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,856
+41.22%
|
$194,832
$22.58 P/Share
|
|
Dec 10
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
179,865
+35.03%
|
$539,595
$3.2 P/Share
|
|
Nov 18
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
24,936
-98.94%
|
$922,632
$37.94 P/Share
|
|
Nov 18
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
24,936
+49.73%
|
$74,808
$3.42 P/Share
|